MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.

doi:10.1158/1078-0432.CCR-07-0609

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Jul 2007

Hirata Hiroshi, Hinoda Yuji, Kikuno Nobuyuki, Kawamoto Ken, Suehiro Yutaka, Tanaka Yuichiro, Dahiya Rajvir

Abstract excerpt

PURPOSE: MDM2 is a major negative regulator of p53, and a single nucleotide polymorphism in the MDM2 promoter region SNP309 (rs2279744) has been shown to increase the affinity of the transcriptional activator Sp1, resulting in elevated MDM2 transcription and expression in some cancers. There is currently no information about the role of MDM2 polymorphism in renal cell carcinoma (RCC). We investigated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Renal Cell

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Expression Regulation, Neoplastic

Share to Kidney Neoplasms

Share to Prognosis

Share to Proto-Oncogene Proteins c-mdm2

Share to Survival Analysis

Share to Transcription, Genetic

Share to Tumor Suppressor Protein p53

Source

Open in PubMed

Identifiers

PMID: 17634539
DOI: 10.1158/1078-0432.CCR-07-0609

Genes

MDM2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.PMID 17634539Read ↗

MDM2 SNP309 contributes to tumor susceptibility: a meta-analysis.Semantic proximity Read ↗

MDM2 promoter polymorphism SNP309 contributes to tumor susceptibility: evidence from 21 case-control studies.Semantic proximity Read ↗

The T309G murine double minute 2 gene polymorphism is an independent prognostic factor for patients with renal cell carcinoma.Semantic proximity Read ↗

MDM2 SNP309, gene-gene interaction, and tumor susceptibility: an updated meta-analysis.Semantic proximity Read ↗

MDM2 SNP309T>G polymorphism with hepatocellular carcinoma risk: a meta-analysis.Semantic proximity Read ↗

MDM2 SNP309 polymorphism is associated with colorectal cancer risk.Semantic proximity Read ↗

Current evidence on the relationship between SNP309 polymorphism in the MDM2 gene and colorectal cancer risk.Semantic proximity Read ↗

An updated meta-analysis on the association of MDM2 SNP309 polymorphism with colorectal cancer risk.Semantic proximity Read ↗

Association between MDM2 SNP309, p53 Arg72Pro, and hepatocellular carcinoma risk: A MOOSE-compliant meta-analysis.Semantic proximity Read ↗

MDM2 SNP309 polymorphism and colorectal cancer risk: a meta-analysis.Semantic proximity Read ↗

MDM2 SNP309T>G polymorphism and hepatocellular carcinoma risk: a meta-analysis.Semantic proximity Read ↗

Association of breast cancer outcome with status of p53 and MDM2 SNP309.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.